KRAS and neoplasm: In models of KRAS G12C oncogenic-driven non-small cell lung carcinoma, orally delivered FAK inhibitors radio-sensitize tumors (Tang et al., 2016), synergize with inhibitors of KRAS G12C (Zhang et al., 2021) and boost checkpoint inhibitor immune responses (Qiao et al., 2024) via tumor intrinsic and extrinsic mechanisms.